Topic
Jubilant Therapeutics
Global News
15 Feb 2023
Jubilant Therapeutics receives Orphan Drug Designation for PRMT5 inhibitor – JBI-778
The drug is used for the treatment of Glioblastoma Multiforme Jubilant Therapeutics, a clinical-stage biopharmaceutical company advancing small molecule precision…
Global News
18 Aug 2021
Jubilant Therapeutics strengthens Board of Directors
Appoints Dr Leila Alland and Dr Jeremy Barton as strategic advisor and Interim CMO Jubilant Therapeutics announced the appointments of…